John Leite serves as the Chief Commercial Officer, CLIA at Veracyte Inc., a leading genomic diagnostics company focused on improving patient care through advanced testing solutions. In his role, Leite is responsible for overseeing the commercial strategy and operations of Veracyte's Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories. His leadership is instrumental in driving the adoption of Veracyte's innovative tests, which help physicians make more informed treatment decisions for patients with cancer and other diseases. Leite brings a wealth of experience in the diagnostics industry to his position at Veracyte. Prior to joining the company, he held several senior leadership roles at notable organizations, including Thermo Fisher Scientific and Quest Diagnostics. At Thermo Fisher Scientific, Leite served as the President of the Transplant Diagnostics business, where he successfully led the global expansion of the company's transplant testing portfolio. Before that, he spent over a decade at Quest Diagnostics, rising to the position of Vice President of Sales and Marketing for the company's oncology and genetic testing division. Throughout his career, Leite has demonstrated a strong track record of driving growth and innovation in the diagnostics field. Under Leite's guidance, Veracyte has continued to expand its CLIA laboratory operations and enhance its commercial capabilities. His strategic vision and deep understanding of the market have been crucial in positioning Veracyte's tests as valuable tools for clinicians and patients alike. Leite's leadership has helped Veracyte strengthen its position as a pioneer in genomic diagnostics, and his contributions have been vital to the company's ongoing success and growth.